NVRO vs. SKIN, IRMD, OSUR, OFIX, PLSE, CVRX, BVS, NPCE, SRDX, and RCEL
Should you be buying Nevro stock or one of its competitors? The main competitors of Nevro include Beauty Health (SKIN), Iradimed (IRMD), OraSure Technologies (OSUR), Orthofix Medical (OFIX), Pulse Biosciences (PLSE), CVRx (CVRX), Bioventus (BVS), NeuroPace (NPCE), Surmodics (SRDX), and AVITA Medical (RCEL). These companies are all part of the "surgical & medical instruments" industry.
Beauty Health (NASDAQ:SKIN) and Nevro (NYSE:NVRO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.
Beauty Health presently has a consensus price target of $6.50, indicating a potential upside of 96.37%. Nevro has a consensus price target of $21.23, indicating a potential upside of 72.75%. Given Nevro's higher probable upside, analysts clearly believe Beauty Health is more favorable than Nevro.
93.3% of Beauty Health shares are held by institutional investors. Comparatively, 95.5% of Nevro shares are held by institutional investors. 41.7% of Beauty Health shares are held by company insiders. Comparatively, 3.0% of Nevro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Beauty Health has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Nevro has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.
Nevro has higher revenue and earnings than Beauty Health. Nevro is trading at a lower price-to-earnings ratio than Beauty Health, indicating that it is currently the more affordable of the two stocks.
Nevro received 464 more outperform votes than Beauty Health when rated by MarketBeat users. Likewise, 66.10% of users gave Nevro an outperform vote while only 49.37% of users gave Beauty Health an outperform vote.
Nevro has a net margin of -21.69% compared to Nevro's net margin of -25.65%. Nevro's return on equity of -18.85% beat Beauty Health's return on equity.
In the previous week, Beauty Health had 8 more articles in the media than Nevro. MarketBeat recorded 18 mentions for Beauty Health and 10 mentions for Nevro. Nevro's average media sentiment score of 0.97 beat Beauty Health's score of -0.28 indicating that Beauty Health is being referred to more favorably in the media.
Summary
Beauty Health beats Nevro on 10 of the 18 factors compared between the two stocks.
Get Nevro News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
